Human immunodeficiency virus‐associated lung cancer in the era of highly active antiretroviral therapy
Open Access
- 28 June 2011
- Vol. 118 (1), 164-172
- https://doi.org/10.1002/cncr.26242
Abstract
BACKGROUND: Lung cancer is the leading cause of death among non‐acquired immunodeficiency syndrome (AIDS)‐defining malignancies. Because highly active antiretroviral therapy (HAART) has improved the survival of patients with human immunodeficiency virus (HIV), the authors evaluated lung cancer outcomes in the HAART era. METHODS: HIV‐positive patients who were diagnosed with lung cancer at the authors' institution during the HAART era (1995‐2008) were analyzed. Patient charts were reviewed for clinical and laboratory data. The CD4 count at diagnosis was treated as a continuous variable and subcategorized into distinct variables with 3 cutoff points (50 cells/mL, 200 cells/mL, and 500 cells/mL). Pearson correlation coefficients were estimated for each covariate studied. Survival was determined by using the Kaplan‐Meier method. RESULTS: Of 80 patients, 73 had nonsmall cell lung cancer. Baseline characteristics were as follows: median patient age, 52 years; male, 80%; African Americans, 84%; injection drug users, 25%; smokers, 100%; and previous exposure to antiretroviral agents, 55%. At the time of cancer diagnosis, the mean CD4 count was 304 cells/mL, and the mean viral load was 82,420 copies/mL. The latency between HIV diagnosis and lung cancer diagnosis was significantly shorter among women (4.1 years vs 7.7 years; P = .02), and 71% of patients received anticancer therapy. The 1‐year and 3‐year survival rates for stage IIIB/IV were 25% and 0%, respectively. Grade 3/4 toxicities occurred in 60% of patients who received chemoradiation versus 36% of patients who received chemotherapy. Cancer‐related survival was better for patients with CD4 counts >200 cells/mL (P = .0298) and >500 cells/mL (P = .0076). CONCLUSIONS: The latency from diagnosis of HIV to lung cancer was significantly shorter for women. Although outcomes for patients with lung cancer who have HIV remain poor, a high CD4 count was associated with improved lung cancer‐related survival. Cancer 2012;. © 2011 American Cancer Society.Keywords
This publication has 41 references indexed in Scilit:
- Incidence of Malignancies in HIV‐Infected Patients and Prognostic Role of Current CD4 Cell Count: Evidence from a Large Italian Cohort StudyClinical Infectious Diseases, 2010
- Lung Cancer and Hormone Replacement Therapy: Association in the Vitamins and Lifestyle StudyJournal of Clinical Oncology, 2010
- HIV As a Risk Factor for Lung Cancer in Women: Data From the Women's Interagency HIV StudyJournal of Clinical Oncology, 2010
- Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort studyThe Lancet Oncology, 2009
- A Meta-Analysis of the Incidence of Non-AIDS Cancers in HIV-Infected IndividualsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2009
- Incidence of Non-AIDS-Defining Malignancies in HIV-Infected Versus Noninfected Patients in the HAART Era: Impact of ImmunosuppressionJAIDS Journal of Acquired Immune Deficiency Syndromes, 2009
- Effect of Cigarette Smoking on HIV Acquisition, Progression, and MortalityAIDS Education and Prevention, 2009
- HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignanciesAIDS, 2008
- Hormone Replacement Therapy Is Associated With Decreased Survival in Women With Lung CancerJournal of Clinical Oncology, 2006
- Human immunodeficiency virus and lung cancerBritish Journal of Surgery, 1997